Med hensyn til indikationen ved nyligt myokardieinfarkt bemærkede CHMP, at denne indikation i nogle medlemsstater var begrænset til patienter, der er intolerante over for ACE- hæmmere.
Regarding the indication in recent myocardial infarction the CHMP noted that this indication was limited to patients intolerants to ACE inhibitors in some Member States.